(MENAFN- PR Newswire) DUBLIN, March 8, 2024 /PRNewswire/ -- The
"Global Carglumic Acid Market by Dosage Form, by Distribution Channel, and By Region" report has been added to
ResearchAndMarkets's offering.
The global carglumic acid market size was estimated to be USD 139.4 million in 2023 and is expected to reach USD 309.2 million by 2034 with a CAGR of 7.51% during the forecast period 2024-2034.
Rising prevalence of urea cycle disorders, expanding applications beyond UCDs, increasing disposable income and improved healthcare infrastructure, orphan drug status and limited competition, technological advancements and product development, growing focus on personalized medicine and early diagnosis, and strategic partnerships and collaborations will drive the market growth.
The uncommon hereditary metabolic diseases known as UCDS impair the body's capacity to metabolize ammonia, a hazardous waste product. Demand has grown since carglumic acid is an essential therapy for several UCDs, most notably N-acetylglutamate synthase deficiency (NAGS deficiency). Increased diagnoses of UCD instances are fueled by rising awareness and better diagnostics, which further propels market expansion.
By dosage form, the dispersible tablets segment accounted for the highest revenue-grossing segment in the global carglumic acid market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference among healthcare professionals and patients for this convenient and easily administrable dosage form. The dispersible tablets offer improved patient compliance, ease of consumption, and efficient absorption, driving their adoption for the treatment of hyperammonemia, thereby contributing significantly to the overall market expansion.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global carglumic acid market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of hyperammonemia cases requiring immediate medical attention, coupled with the crucial role played by hospital pharmacies in the distribution and administration of specialized medications. The close collaboration between healthcare professionals and hospital pharmacies ensures prompt access to Carglumic Acid for patients in need, driving the segment's financial performance.
The North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increased awareness of metabolic disorders, and a growing number of diagnosed cases of hyperammonemia. Additionally, favorable reimbursement policies, advanced research and development activities, and a proactive regulatory environment contribute to the region's dominance in the Carglumic Acid market.
Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of rare genetic disorders, a rising incidence of metabolic diseases, and efforts to enhance healthcare infrastructure. Additionally, expanding healthcare expenditure, improving access to medical treatments, and a growing emphasis on early disease diagnosis contribute to the significant market potential in the Asia Pacific.
Report Scope:
Base Year: 2023 Forecast Period: 2024-2034 Study Coverage Market Forecast by Dosage Form, and Distribution Channel Market Forecast for 5 Regions and 17+ Countries North America (U.S. and Canada) Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe) Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC) Latin America (Brazil, Mexico, Argentina, Rest of LATAM) MEA (South Africa, GCC, Rest of MEA)
Company Profiles of the Top 10+ Major Market Players
Key Topics Covered:
1. Research Methodology
2. Introduction
2.1. Market Definition
2.2. Global Carglumic Acid Market Overview
3. Executive Summary
4. Market Environment Analysis
5. Market Dynamics
6. COVID-19 Impact Analysis
7. Carglumic Acid Market: Dosage Form Estimates & Trend Analysis
7.1. Dosage Form Segment Opportunity Analysis
7.2. Orally Disintegrating Tablets
7.3. Dispersible Tablets
7.4. Other Dosage Forms
8. Carglumic Acid Market: Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel Segment Opportunity Analysis
8.2. Hospital Pharmacies
8.3. Retail Pharmacies
8.4. E-commerce Channels
9. Regional Market Analysis
10. North America Carglumic Acid Market
11. Europe Global Carglumic Acid Market
12. Asia Pacific Global Carglumic Acid Market
13. Latin America Global Carglumic Acid Market
14. MEA Global Carglumic Acid Market
15. Competitor Analysis
15.1. Company Market Share Analysis, 2023
15.2. Major Recent Developments
16. Company Profiles
Recordati Dipharma Francis S.r.l. Lucane Pharma Sigma-Aldrich Novartis Rare Disease Therapeutics Inc. Beijing Continent Pharmaceuticals Co.
United States Pharmacopeia (USP) Aceto Corporation Hangzhou Hyper Chemicals MedChemExpress AlliChem TCI America Tokyo Chemical Industry Co. VIO Chemicals.
For more information about this report visit
About ResearchAndMarkets
ResearchAndMarkets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo:
SOURCE Research and Markets
MENAFN08032024003732001241ID1107952404
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.